SAN DIEGO (EGMN) – Stretching out the delivery of rituximab significantly improved overall and event-free survival among older patients with poor-prognosis diffuse large B-cell lymphoma, German investigators reported. Patients older than 60 years who had diffuse large B-cell lymphoma (DLBCL) were treated with the CHOP regimen and rituximab (Rituxan) on days 4 and 1 before CHOP and at increasing intervals thereafter, in the SMARTE-R-CHOP-14 trial.Those with poor-prognosis disease had an overall survival...